-
1
-
-
78149467425
-
Deux nouveaux anticoagulants disponibles en 2010 - dabigatran étexilate et rivaroxaban: progrès attendus - problèmes posés
-
Samama M.M., Conard J., Horellou M.H., Le Flem L., Guinet C., Depasse F. Deux nouveaux anticoagulants disponibles en 2010 - dabigatran étexilate et rivaroxaban: progrès attendus - problèmes posés. Ann Pharm Fra 2010, 68:359-369.
-
(2010)
Ann Pharm Fra
, vol.68
, pp. 359-369
-
-
Samama, M.M.1
Conard, J.2
Horellou, M.H.3
Le Flem, L.4
Guinet, C.5
Depasse, F.6
-
2
-
-
80052627217
-
Trois nouveaux anticoagulants disponibles en 2011: dabigatran étexilate, rivaroxaban et apixaban
-
Samama M.M., Gerotziafas G. Trois nouveaux anticoagulants disponibles en 2011: dabigatran étexilate, rivaroxaban et apixaban. Biotribune 2011, 38:10-15.
-
(2011)
Biotribune
, vol.38
, pp. 10-15
-
-
Samama, M.M.1
Gerotziafas, G.2
-
3
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
-
(2009)
N Engl J Med
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh, A.6
-
4
-
-
80052592404
-
Rivaroxaban versus warfarin in non valvular atrial fibrillation
-
Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in non valvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
-
(2011)
N Engl J Med
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
Pan, G.4
Singer, D.E.5
Hacke, W.6
-
5
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
-
(2011)
N Engl J Med
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
Lopes, R.D.4
Hylek, E.M.5
Hanna, M.6
-
6
-
-
78649980897
-
Pharmacologic properties of the new oral anticoagulants: a clinician oriented review with a focus on perioperative management
-
Douketis J.D. Pharmacologic properties of the new oral anticoagulants: a clinician oriented review with a focus on perioperative management. Curr Pharm Des 2010, 16:3436-3441.
-
(2010)
Curr Pharm Des
, vol.16
, pp. 3436-3441
-
-
Douketis, J.D.1
-
7
-
-
80052395334
-
Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct: propositions du Groupe d'intérêt en hémostase périopératoire (GIHP) et du Groupe d'études sur lthom
-
Sie P., Samama C.M., Godier A., Rosencher N., Steib A., Llau J.V., et al. Chirurgies et actes invasifs chez les patients traités au long cours par un anticoagulant oral anti-IIa ou anti-Xa direct: propositions du Groupe d'intérêt en hémostase périopératoire (GIHP) et du Groupe d'études sur l'hémostase et la thrombose (GEHT). Ann Fr Anesth Reanim 2001, 30:645-650.
-
(2001)
Ann Fr Anesth Reanim
, vol.30
, pp. 645-650
-
-
Sie, P.1
Samama, C.M.2
Godier, A.3
Rosencher, N.4
Steib, A.5
Llau, J.V.6
-
8
-
-
82555172355
-
Dabigatran: review of pharmacology and management of bleeding complications of this novel anticoagulant
-
Ganetsky M., Babu K.M., Salhanick S.D., Brown R.S., Boyer E.N. Dabigatran: review of pharmacology and management of bleeding complications of this novel anticoagulant. J Med Toxicol 2011, 7:281-287.
-
(2011)
J Med Toxicol
, vol.7
, pp. 281-287
-
-
Ganetsky, M.1
Babu, K.M.2
Salhanick, S.D.3
Brown, R.S.4
Boyer, E.N.5
-
9
-
-
77953168824
-
Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity
-
Van Ryn J., Stangier J., Haertter S., Liesenfeld K.H., Wienen W., Feuring M., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2011, 103:1116-1127.
-
(2011)
Thromb Haemost
, vol.103
, pp. 1116-1127
-
-
Van Ryn, J.1
Stangier, J.2
Haertter, S.3
Liesenfeld, K.H.4
Wienen, W.5
Feuring, M.6
-
10
-
-
80053571188
-
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
-
Eerenberg E.S., Kamphuisen P.W., Sijpkens M.K., Meijers J.C., Buller H.R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
-
(2011)
Circulation
, vol.124
, pp. 1573-1579
-
-
Eerenberg, E.S.1
Kamphuisen, P.W.2
Sijpkens, M.K.3
Meijers, J.C.4
Buller, H.R.5
Levi, M.6
-
11
-
-
79960955075
-
The use of dabigatran in elderly patients
-
Legrand M., Mateo F., Aribaud A., Ginisty S., Eftekhari P., Tran Ba Huy P., et al. The use of dabigatran in elderly patients. Arch Intern Med 2011, 171:1285-1288.
-
(2011)
Arch Intern Med
, vol.171
, pp. 1285-1288
-
-
Legrand, M.1
Mateo, F.2
Aribaud, A.3
Ginisty, S.4
Eftekhari, P.5
Tran Ba Huy, P.6
-
12
-
-
84861990990
-
Laboratory follow-up and clinical management of a patient case with severe bleeding complication on dabigatran for atrial fibrillation
-
Lassila R., Munsterhjelm E., Joutsi-Korhonen L., Armstrong E. Laboratory follow-up and clinical management of a patient case with severe bleeding complication on dabigatran for atrial fibrillation. J Thromb Haemost 2011, 9(Suppl. 2):840-841.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.SUPPL. 2
, pp. 840-841
-
-
Lassila, R.1
Munsterhjelm, E.2
Joutsi-Korhonen, L.3
Armstrong, E.4
-
13
-
-
77953394559
-
Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meeting
-
Lu G., DeGuzman F.R., Lakhotia S., Hollenbach S.J., Phillips D.R., Sinha U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meeting. Blood 2008, 112:983.
-
(2008)
Blood
, vol.112
, pp. 983
-
-
Lu, G.1
DeGuzman, F.R.2
Lakhotia, S.3
Hollenbach, S.J.4
Phillips, D.R.5
Sinha, U.6
-
14
-
-
84861975957
-
An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models? ISTH Kyoto
-
Van Ryn J., Litzenburger T., Waterman A., Canada K., Hauel N., Sarko C., et al. An antibody selective to dabigatran safely neutralizes both dabigatran-induced anticoagulant and bleeding activity in in vitro and in vivo models? ISTH Kyoto. J Thromb Haemost 2011, 9(Suppl. 2):110.
-
(2011)
J Thromb Haemost
, vol.9
, Issue.SUPPL. 2
, pp. 110
-
-
Van Ryn, J.1
Litzenburger, T.2
Waterman, A.3
Canada, K.4
Hauel, N.5
Sarko, C.6
-
15
-
-
84861990943
-
-
Carnet-conseils. Vous et votre nouveau traitement anticoagulant site
-
Carnet-conseils. Vous et votre nouveau traitement anticoagulant site http://www.gita-thrombose.org/.
-
-
-
-
16
-
-
80052145294
-
A patient's guide to taking dabigatran etexilate
-
Spinler S.A., Willey V.J. A patient's guide to taking dabigatran etexilate. Circulation 2011, 124:209-211.
-
(2011)
Circulation
, vol.124
, pp. 209-211
-
-
Spinler, S.A.1
Willey, V.J.2
-
17
-
-
84858415439
-
Important data after drug approval: comment on dabigatran association with higher risk of acute coronary events
-
Redberg R.F. Important data after drug approval: comment on dabigatran association with higher risk of acute coronary events. Arch Intern Med 2012, 10.1001/archinternmed.2011.2169.
-
(2012)
Arch Intern Med
-
-
Redberg, R.F.1
|